person · Reporting owner

Norwalk Leslie V

Disclosed activity across 10 companies

Tapewire entity: 14658
SEC CIK: 0001533568

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ARVINAS, INC.ARVN · Entity 5355	Director	June 24, 2026	June 26, 2026
CENTENE CORPCNC · Entity 3133	Director	March 31, 2022	April 05, 2022
CVS HEALTH CorpCVS · Entity 2884	Director	May 14, 2026	May 15, 2026
ENDOLOGIX INC /DE/ELGX · Entity 146591	Director	August 05, 2019	August 06, 2019
GLOBUS MEDICAL INCGMED · Entity 3496	Director	January 21, 2026	January 23, 2026
ModivCare IncMODV · Entity 76927	Director	February 14, 2024	February 16, 2024
NEUROCRINE BIOSCIENCES INCNBIX · Entity 2655	Director	July 28, 2026	July 30, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ARVINAS, INC.

Report date June 24, 2026 · Filed June 26, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	41,572	Reported balance After 2026-06-24 transaction · row 1 1 source row Row 1 · 2026-06-24 · Grant · Acquired 15,527 · Balance 41,572 F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.05 · Expires 2036-06-23	Direct	22,714	Reported balance After 2026-06-24 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-24 · Grant · Acquired 22,714 · Balance 22,714 F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

F2: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date.

CENTENE CORP

Report date March 31, 2022 · Filed April 05, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,481.005	Reported balance After 2022-03-31 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-03-31 · Grant · Acquired 381.005 · Balance 1,481.005 F1: Ownership includes 1,100 shares of restricted stock units subject to vesting requirements.
Common Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $80.57 · Expires 2032-02-07	Direct	10,000	Reported balance Holding disclosure · report date 2022-03-31 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 10,000

Filing footnotes · ownership attribution and instrument terms

F1: Ownership includes 1,100 shares of restricted stock units subject to vesting requirements.

CVS HEALTH Corp

Report date May 14, 2026 · Filed May 15, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,376	Reported balance After 2026-05-14 transaction · row 1 1 source row Row 1 · 2026-05-14 · Grant · Acquired 1,447 · Balance 7,376 F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

ENDOLOGIX INC /DE/

Report date August 05, 2019 · Filed August 06, 2019

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	29,932	Reported balance After 2019-08-05 transaction · row 1 1 source row Row 1 · 2019-08-05 · Grant · Acquired 13,494 · Balance 29,932 F1: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock.
Option to PurchaseSEC Table II · derivative / convertible security · Conversion / exercise price $6.67 · Expires 2029-08-05	Direct	9,023	Reported balance After 2019-08-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-08-05 · Grant · Acquired 9,023 · Balance 9,023 F2: 100% of the option award shall vest on August 5, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: 100% of the time-based restricted stock unit award shall vest on August 5, 2020 and shall settle in shares of common stock.

F2: 100% of the option award shall vest on August 5, 2020.

GLOBUS MEDICAL INC

Report date January 21, 2026 · Filed January 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy Class A Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $94.15 · Expires 2036-01-21	Direct	15,000	Reported balance After 2026-01-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-01-21 · Grant · Acquired 15,000 · Balance 15,000 F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: These options were granted on January 21, 2026, and will vest on January 1, 2027.

ModivCare Inc

Report date February 14, 2024 · Filed February 16, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	18,830	Reported balance After 2024-02-14 transaction · row 1 1 source row Row 1 · 2024-02-14 · Grant · Acquired 2,658 · Balance 18,830 F1: Represents restricted shares scheduled to fully vest on February 14, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted shares scheduled to fully vest on February 14, 2025.

NEUROCRINE BIOSCIENCES INC

Report date July 28, 2026 · Filed July 30, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,430	Ending reported balance After 2026-07-29 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-28 · Sale · Disposed 1,250 · Balance 1,588 F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-07-29 · Exercise / conversion · Acquired 842 · Balance 2,430
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $139.43 · Expires 2034-05-22	Direct	2,140	Reported balance After 2026-07-29 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-07-29 · Exercise / conversion · Disposed 842 · Balance 2,140 F3: Option vested in 12 monthly installments beginning June 22, 2024.

Filing footnotes · ownership attribution and instrument terms

F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3: Option vested in 12 monthly installments beginning June 22, 2024.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

MAGELLAN HEALTH INC

Report date January 04, 2022 · Filed January 04, 2022

Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative	Direct	0	Reported balance After 2022-01-04 transaction · row 1 1 source row Row 1 · 2022-01-04 · Disposition to issuer · Disposed 5,698 · Balance 0 F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").

F2: Includes 2,911 restricted shares of Common Stock. In accordance with the terms of the Merger Agreement, at the effective time of the Merger, each of these restricted shares of Common Stock was automatically cancelled and converted into the right to receive the Merger Consideration.

NUVASIVE INC

Report date September 01, 2023 · Filed September 05, 2023

Section 16 reporting ended · disclosed 2023-09-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common Stock, par value $0.001 per shareSEC Table I · non-derivative	Direct	Reported balance After 2023-09-01 transaction · row 1 1 source row Row 1 · 2023-09-01 · Disposition to issuer · Disposed 3,095 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-09-01 · Disposition to issuer · Disposed 5,960 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-09-01 · Disposition to issuer · Disposed 3,725 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-09-01 · Disposition to issuer · Disposed 2,501 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-09-01 · Disposition to issuer · Disposed 2,822 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-09-01 · Disposition to issuer · Disposed 2,130 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Disposition to issuer · Disposed 3,230 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-01 · Disposition to issuer · Disposed 2,577 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-01 · Disposition to issuer · Disposed 2,702 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-09-01 · Disposition to issuer · Disposed 3,788 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.
Restricted StockSEC Table II · derivative / convertible security	Direct	Reported balance After 2023-09-01 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2023-09-01 · Disposition to issuer · Disposed 4,816 · Balance 0 F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger (the "Effective Time"), each share of the Issuer's common stock issued and outstanding immediately prior to the Effective Time (other than certain excluded shares) was cancelled and converted into the right to receive 0.75 shares of Class A common stock of Globus ("Globus Class A Common Stock"), par value $0.001 per share (the "Exchange Ratio" and such shares, the "Merger Consideration"), and cash in lieu of fractional shares.

F2: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award.

Press Ganey Holdings, Inc.

Report date October 21, 2016 · Filed October 25, 2016

Section 16 reporting ended · disclosed 2016-10-25. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2016-10-21 transaction · row 1 1 source row Row 1 · 2016-10-21 · Disposition to issuer · Disposed 28,770 · Balance 0

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 29, 2026 Filed Jul 30, 2026 21:29 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	842	$0.00 Strike: $139.43	$0.00	Disclosure SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · derivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,140 Underlying: Common Stock · 842 shares Expires 2034-05-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vested in 12 monthly installments beginning June 22, 2024. Read SEC document
July 29, 2026 Filed Jul 30, 2026 21:29 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	842	$139.43	$117,400.06	Disclosure SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · nonDerivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 28, 2026 Filed Jul 30, 2026 21:29 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,250	$182.01	$227,507.50	Disclosure SEC source: 0001533568-26-000012 · wk-form4_1785446949.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,588 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $182.00 to $182.03. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:23 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	22,714	$0.00 Strike: $8.05	$0.00	Disclosure SEC source: 0001628280-26-045787 · wk-form4_1782505378.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,714 Underlying: Common Stock · 22,714 shares Expires 2036-06-23 F2 · derivative.exercise_date: This option award was granted on June 24, 2026. The shares underlying the award shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document
June 24, 2026 Filed Jun 26, 2026 20:23 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantCommon Stock	15,527	$0.00	$0.00	Disclosure SEC source: 0001628280-26-045787 · wk-form4_1782505378.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,572 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 24, 2026 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of (i) June 24, 2027 or (ii) immediately prior to the first annual meeting of stockholders occurring after the date of grant, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document
June 04, 2026 Filed Jun 8, 2026 22:07 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,250	$168.06	$210,071.63	Disclosure SEC source: 0001533568-26-000009 · wk-form4_1780956471.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,838 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.00 to $168.2550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
May 27, 2026 Filed May 29, 2026 22:01 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	2,624	$0.00 Strike: $155.83	$0.00	Disclosure SEC source: 0001533568-26-000007 · wk-form4_1780092090.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,624 Underlying: Common Stock · 2,624 shares Expires 2036-05-27 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 27, 2026. Read SEC document
May 27, 2026 Filed May 29, 2026 22:01 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestriced Stock Unit · Derivative	1,284	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001533568-26-000007 · wk-form4_1780092090.xml · derivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,284 Underlying: Common Stock · 1,284 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 27, 2027. F2 · derivative.expiration_date: The RSUs will vest in full on May 27, 2027. Read SEC document
May 21, 2026 Filed May 21, 2026 23:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001533568-26-000005 · wk-form4_1779405735.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,659 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. F2 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 21, 2025 and is fully vested. Read SEC document
May 21, 2026 Filed May 21, 2026 23:22 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,659	$0.00	$0.00	Disclosure SEC source: 0001533568-26-000005 · wk-form4_1779405735.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2026 Filed May 15, 2026 21:12 UTC	CVS HEALTH Corp CVS · Entity 2884	GrantCommon Stock	1,447	$97.15	$140,576.05	Disclosure SEC source: 0000064803-26-000070 · form4.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,376 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document
May 12, 2026 Filed May 14, 2026 20:45 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	3,810	$155.01	$590,601.05	Disclosure SEC source: 0001533568-26-000003 · wk-form4_1778791511.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,429 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted and effective on September 15, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.00 to $155.0550. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
January 21, 2026 Filed Jan 23, 2026 22:12 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $94.15	$0.00	Disclosure SEC source: 0001193125-26-021266 · ownership.xml · derivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2036-01-21 F1 · derivative.exercise_date: These options were granted on January 21, 2026, and will vest on January 1, 2027. Read SEC document
January 08, 2026 Filed Jan 12, 2026 22:36 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	2,000	$101.10	$202,200.00	Disclosure SEC source: 0001193125-26-010697 · ownership.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,419 F1 · kind: This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated September 12, 2025 executed by the reporting person. Read SEC document
December 16, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,190	$155.09	$184,558.41	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 4 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,239 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F3 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.09 to $155.40. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	1,724	$0.00 Strike: $84.95	$0.00	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · derivative · entry 6 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,724 shares Expires 2032-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on May 18, 2022 and vested in 12 equal monthly installments beginning June 18, 2022. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	8,276	$0.00 Strike: $92.35	$0.00	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · derivative · entry 5 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 557 Underlying: Common Stock · 8,276 shares Expires 2031-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on May 19, 2021 and vested in 12 equal monthly installments beginning June 19, 2021. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	5,000	$152.23	$761,143.50	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,429 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on September 12, 2025. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $151.79 to $152.82. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,724	$84.95	$146,453.80	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 15, 2025 Filed Dec 17, 2025 21:24 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	8,276	$92.35	$764,288.60	Disclosure SEC source: 0001533568-25-000007 · wk-form4_1766006643.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 12, 2025 Filed Dec 16, 2025 21:18 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	4,000	$88.85	$355,400.00	Disclosure SEC source: 0001193125-25-320898 · ownership.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,419 F1 · kind: This sale was effectuated pursuant to a Rule 10b5-1 Trading Plan dated September 12, 2025 executed by the reporting person. Read SEC document
November 20, 2025 Filed Nov 21, 2025 22:44 UTC	CVS HEALTH Corp CVS · Entity 2884	GrantCommon Stock	1,652	$76.04	$125,618.08	Disclosure SEC source: 0000064803-25-000064 · form4.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,929 F1 · shares: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document
June 25, 2025 Filed Jun 28, 2025 01:07 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	23,105	$0.00 Strike: $7.80	$0.00	Disclosure SEC source: 0001655759-25-000112 · wk-form4_1751072831.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,105 Underlying: Common Stock · 23,105 shares Expires 2035-06-24 F2 · derivative.exercise_date: This option award was granted on June 25, 2025. The shares underlying the award shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document
June 25, 2025 Filed Jun 28, 2025 01:07 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantCommon Stock	16,025	$0.00	$0.00	Disclosure SEC source: 0001655759-25-000112 · wk-form4_1751072831.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,045 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on June 25, 2025 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of June 25, 2026 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders, subject to the reporting person's continued service with the Issuer on the vesting date. Read SEC document
May 22, 2025 Filed May 22, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000126 · wk-form4_1747948480.xml · derivative · entry 4 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,435 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 22, 2024 and is fully vested. Read SEC document
May 22, 2025 Filed May 22, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	1,435	$0.00	$0.00	Disclosure SEC source: 0000914475-25-000126 · wk-form4_1747948480.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2025 Filed May 22, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	3,305	$0.00 Strike: $120.56	$0.00	Disclosure SEC source: 0000914475-25-000126 · wk-form4_1747948480.xml · derivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,305 Underlying: Common Stock · 3,305 shares Expires 2035-05-21 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 21, 2025. Read SEC document
May 21, 2025 Filed May 22, 2025 21:14 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,659	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-25-000126 · wk-form4_1747948480.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,659 Underlying: Common Stock · 1,659 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 21, 2026. F2 · derivative.expiration_date: The RSUs will vest in full on May 21, 2026. Read SEC document
May 15, 2025 Filed May 19, 2025 21:47 UTC	CVS HEALTH Corp CVS · Entity 2884	GrantCommon Stock	2,077	$60.47	$125,596.19	Disclosure SEC source: 0001127602-25-014957 · form4.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,277 F1 · kind: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the 2017 Incentive Compensation Plan. Read SEC document
January 23, 2025 Filed Mar 28, 2025 23:07 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $92.42	$0.00	Disclosure SEC source: 0000950170-25-047041 · ownership.xml · derivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2035-01-23 F1 · derivative.exercise_date: These options were granted on January 23, 2025, and will vest on January 1, 2026. Read SEC document
November 21, 2024 Filed Nov 25, 2024 22:55 UTC	CVS HEALTH Corp CVS · Entity 2884	GrantCommon Stock	2,200	$57.10	$125,620.00	Disclosure SEC source: 0001127602-24-028008 · form4.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,200 F1 · shares: Consists of common stock issued in payment of a semi-annual retainer, at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Read SEC document
July 11, 2024 Filed Jul 15, 2024 20:25 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	1,000	$70.00	$70,000.00	Disclosure SEC source: 0000950170-24-083594 · ownership.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,419 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated December 14, 2023 executed by the reporting person. Read SEC document
May 29, 2024 Filed May 31, 2024 21:50 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantStock Option (right to buy) · Derivative	9,070	$0.00 Strike: $33.90	$0.00	Disclosure SEC source: 0001655759-24-000081 · wk-form4_1717192234.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,070 Underlying: Common Stock · 9,070 shares Expires 2034-05-28 F2 · derivative.exercise_date: This option award was granted on May 29, 2024. The shares underlying the award shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document
May 29, 2024 Filed May 31, 2024 21:50 UTC	ARVINAS, INC. ARVN · Entity 5355	GrantCommon Stock	5,899	$0.00	$0.00	Disclosure SEC source: 0001655759-24-000081 · wk-form4_1717192234.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,020 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on May 29, 2024 and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs shall vest in full on the earlier of May 29, 2025 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders. Read SEC document
May 22, 2024 Filed May 23, 2024 22:02 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantNon-Qualified Stock Option · Derivative	2,982	$0.00 Strike: $139.43	$0.00	Disclosure SEC source: 0000914475-24-000144 · wk-form4_1716501731.xml · derivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,982 Underlying: Common Stock · 2,982 shares Expires 2034-05-22 F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 22, 2024. Read SEC document
May 22, 2024 Filed May 23, 2024 22:02 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	GrantRestricted Stock Unit · Derivative	1,435	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0000914475-24-000144 · wk-form4_1716501731.xml · derivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,435 Underlying: Common Stock · 1,435 shares Expires not disclosed F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F2 · derivative.exercise_date: The RSUs will vest in full on May 22, 2025. F2 · derivative.expiration_date: The RSUs will vest in full on May 22, 2025. Read SEC document
May 17, 2024 Filed May 21, 2024 21:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionRestricted Stock Unit · Derivative	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000132 · wk-form4_1716325570.xml · derivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting. F4 · derivative.exercise_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. F4 · derivative.expiration_date: This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested. Read SEC document
May 17, 2024 Filed May 21, 2024 21:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	1,106	$141.82	$156,849.93	Disclosure SEC source: 0000914475-24-000132 · wk-form4_1716325570.xml · nonDerivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 994 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 28, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.71. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range Read SEC document
May 17, 2024 Filed May 21, 2024 21:06 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	2,100	$0.00	$0.00	Disclosure SEC source: 0000914475-24-000132 · wk-form4_1716325570.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 15, 2024 Filed Mar 19, 2024 23:40 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	SaleClass A Common Stock	10,590	$51.99	$550,574.10	Disclosure SEC source: 0000950170-24-033817 · ownership.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,419 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan dated December 14, 2023 executed by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at a price range of $51.90 - $52.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares at each separate price within the range set forth in footnote (2) of this Form 4. Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:50 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionNon-Qualified Stock Option · Derivative	8,000	$84.95 Strike: $84.95	$679,600.00	Disclosure SEC source: 0000914475-24-000080 · wk-form4_1709250595.xml · derivative · entry 3 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,724 Underlying: Common Stock · 8,000 shares Expires 2032-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option vests in 12 monthly installments beginning June 18, 2022. Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:50 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	SaleCommon Stock	8,000	$135.67	$1,085,388.00	Disclosure SEC source: 0000914475-24-000080 · wk-form4_1709250595.xml · nonDerivative · entry 2 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 28, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $134.82 to $136.50. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document
February 27, 2024 Filed Feb 29, 2024 23:50 UTC	NEUROCRINE BIOSCIENCES INC NBIX · Entity 2655	Exercise / conversionCommon Stock	8,000	$84.95	$679,600.00	Disclosure SEC source: 0000914475-24-000080 · wk-form4_1709250595.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 14, 2024 Filed Feb 16, 2024 16:35 UTC	ModivCare Inc MODV · Entity 76927	GrantCommon Stock	2,658	$0.00	$0.00	Disclosure SEC source: 0001437749-24-004597 · rdgdoc.xml · nonDerivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,830 F1 · shares: Represents restricted shares scheduled to fully vest on February 14, 2025. Read SEC document
January 26, 2024 Filed Jan 30, 2024 22:09 UTC	GLOBUS MEDICAL INC GMED · Entity 3496	GrantStock Option (Right to Buy Class A Common Stock) · Derivative	15,000	$0.00 Strike: $53.75	$0.00	Disclosure SEC source: 0000950170-24-008957 · ownership.xml · derivative · entry 1 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2034-01-26 F1 · derivative.exercise_date: These options were granted on January 26, 2024, and will vest on January 1, 2025. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:55 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	4,816	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048186 · doc4.xml · derivative · entry 11 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,816 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:55 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	3,788	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048186 · doc4.xml · derivative · entry 10 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,788 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:55 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	2,702	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048186 · doc4.xml · derivative · entry 9 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,702 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:55 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	2,577	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048186 · doc4.xml · derivative · entry 8 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,577 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document
September 01, 2023 Filed Sep 5, 2023 16:55 UTC	NUVASIVE INC NUVA · Entity 110002	Disposition to issuerRestricted Stock · Derivative	3,230	$0.00	$0.00	Disclosure SEC source: 0001209191-23-048186 · doc4.xml · derivative · entry 7 Norwalk Leslie V · CIK 0001533568 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,230 shares Expires not disclosed F2 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive (without interest) the Merger Consideration in respect of each share of Issuer common stock underlying such award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.